Indivior (INDV)
11.23
-0.28 (-2.43%)
At close: Jan 14, 2025, 3:59 PM
11.44
1.88%
Pre-market Jan 15, 2025, 05:11 AM EST
undefined% (undefined)
| Bid | 11.51 |
| Market Cap | 1.40B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.03 |
| PE Ratio (ttm) | -374.3 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 11.55 |
| Volume | 772,681 |
| Avg. Volume (20D) | 1,196,093 |
| Open | 11.35 |
| Previous Close | 11.51 |
| Day's Range | 11.07 - 11.41 |
| 52-Week Range | 7.33 - 23.22 |
| Beta | undefined |
About INDV
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorph...
Sector Healthcare
IPO Date Dec 29, 2014
Employees 1,000
Stock Exchange NASDAQ
Ticker Symbol INDV
Website https://www.indivior.com
Analyst Forecast
According to 2 analyst ratings, the average rating for INDV stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 42.49% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Indivior is scheduled to release its earnings on Feb 20, 2025,
before market opens.
Analysts project revenue of $260.43M, reflecting a -11.12% YoY shrinking and earnings per share of 0.26, making a -39.53% decrease YoY.
Analysts project revenue of $260.43M, reflecting a -11.12% YoY shrinking and earnings per share of 0.26, making a -39.53% decrease YoY.
3 months ago ·
Source
-15.47%
Indivior shares are trading lower after the compan...
Unlock content with
Pro Subscription
5 months ago ·
Source
+20.31%
Indivior shares are trading higher after the company reported better-than-expected Q2 financial results and announced an accelerated $100 million share repurchase program.
